Arbeitsgruppe Neuroendokrine Tumoren/Karzinoide - Studien
| Progressive pancreatic neuroendocrine neoplasms |
|||
| AIO-assoziierte Studie |
für weitere Zentren offen | www.clinicaltrialsregister.eu | zur Studie |
| AIO-NET-0117/ass: A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNet study) |
|||
| --- in Rekrutierung --- | |||
| Neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) | |||
| AIO-assoziierte Studie | für weitere Zentren offen | www.clinicaltrials.gov | zur Studie |
| AIO-NET-0417/ass: A prospective, randomised,
Controlled, Open-label, Multicentre phase III study to evaluate efficacy and
safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide
compared to targeted molecular therapy with Everolimus in patients with
inoperable, progressive, somatostatin receptor-positive (SSTR pos.),
neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET). 177Lu-edotreotide vs. everolimus in GEP-NET (COMPETE-Trial) |
|||
| --- in Rekrutierung --- | |||
| LETZTE AKTUALISIERUNG DIESER SEITE AM: 06.12.2020 |